Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) reported third-quarter results and detailed an intensifying slate of clinical milestones as its QTORIN platform advances across four rare dermatologic diseases — …
Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the development of QTORIN™ pitavastatin, a novel investigational therapy for disseminated superficial actinic porokeratosis (DSAP), a rare and progressive skin disease …
Palvella Unveils New Therapy Targeting Rare Premalignant Skin Disease DSAP Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it will report third-quarter 2025 financial results before markets open on Tuesday, November 11, 2025. Company leadership will host a live …
Palvella Therapeutics to Report Q3 Results, Highlight Progress in Rare Skin Disease Trials Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it has received the second year of funding under its U.S. Food and Drug Administration (FDA) Office of Orphan Products Development …
Palvella Therapeutics Receives Second Year of FDA Grant Funding for Phase 3 SELVA Trial Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it will expand development of its investigational therapy QTORIN™ 3.9% rapamycin anhydrous gel into clinically significant angiokeratomas, a rare and debilitating …
Palvella Expands QTORIN Rapamycin Program Into Rare Angiokeratomas Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it has completed TOIVA, a Phase 2 proof-of-concept trial of QTORIN™ 3.9% rapamycin anhydrous gel, for the treatment of cutaneous venous …
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Cutaneous Venous Malformations Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has completed TOIVA, its Phase 2 clinical trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel as a potential treatment for cutaneous venous malformations …
Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Rare Skin Disorder Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has appointed David W. Osborne, Ph.D., as Chief Innovation Officer, bringing more than 25 years of experience in developing therapies for difficult-to-treat …
Palvella Therapeutics Names David W. Osborne, Ph.D. as Chief Innovation Officer Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced that Chief Executive Officer Wes Kaupinen will present at two major investor conferences in September.
Palvella Therapeutics to Present at Upcoming Healthcare Conferences Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced that Founder and CEO Wes Kaupinen will take part in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. …
Palvella Therapeutics CEO to Speak at Canaccord Genuity Growth Conference Read More